Where sTMS Fits in Prevention: A Clinical Decision Framework
In migraine care, preventive treatment decisions often follow a familiar escalation pattern:
Start with established oral preventives → assess response and tolerability → adjust or switch → consider newer agents → revisit strategy as disease evolves.
But in real-world practice, that pathway is rarely linear.
Patients discontinue medications due to side effects.
Some patients have contraindications from the start.
Others cycle through multiple options before finding partial relief—or none at all.
This is where neuromodulation, including single-pulse transcranial magnetic stimulation (sTMS), can be positioned more clearly in the preventive framework.
Not as a replacement for guideline-based care—but as a parallel option for specific clinical indications.
When to Consider Neuromodulation
A simple way to conceptualize where sTMS fits is to identify three clinical entry points: 1. Medication intolerance or contraindication
- Patients unable to tolerate standard preventive therapies
- Patients with comorbidities limiting pharmacologic options
- Patients with prior adverse effects leading to discontinuation
- Inadequate response after appropriate trials
- Multiple preventive medication failures
- Partial response with persistent functional impairment
- Ongoing disability despite optimized pharmacologic regimens
- Preference for non-pharmacologic strategies
- Strong patient preference to minimize medication burden
- Concerns about polypharmacy or long-term drug exposure
- Desire for non-systemic treatment options
In these scenarios, neuromodulation becomes less of a “last resort” and more of a structured adjunct or alternative pathway.
Contraindication-Driven Rationale
One of the key reasons clinicians consider neuromodulation is not only efficacy, but contraindications of medication use.
Migraine preventive therapy is often limited by:
- Cardiovascular comorbidity concerns
- Pregnancy or family planning considerations
- Polypharmacy in older adults
- Prior intolerance to multiple drug classes
- Patient reluctance after repeated adverse effects
In these contexts, non-pharmacologic interventions may offer a lower systemic burden option that can be integrated into ongoing care.
Importantly, this does not eliminate the need for individualized assessment or ongoing pharmacologic management when appropriate. Rather, it broadens the available options when standard treatment options are limited.
The “Try-Before-Escalation” Model
Traditional migraine prevention often follows a stepwise escalation model.
An emerging complementary approach in some practices is what could be described as a “try-before-escalation” framework for select patients.
In this model:
- Neuromodulation may be introduced earlier in patients with barriers to medication use ● It may be used alongside first-line preventives rather than only after failure ● It serves as a non-pharmacologic option while longer-term medication strategies are optimized
This approach does not replace guideline-based pharmacologic prevention. Instead, it acknowledges that some patients benefit from earlier diversification of treatment modalities.
For clinicians, they value additional treatment options.
For patients, the value is options that do not require sequential failure before access.
A Practical Way to Think About sTMS
Rather than positioning sTMS as “new” or “alternative,” it may be more clinically useful to frame it as:
- A non-systemic neuromodulation option
- A tool for patients with limited pharmacologic pathways
- A strategy for reducing exclusive reliance on medication escalation
- A component of multimodal preventive care
This approach recognizes neuromodulation’s place in practice without overstating its impact.
Final Clinical Perspective
Migraine prevention is rarely about finding a single perfect intervention.
It is about building a sustainable combination of strategies that patients can actually tolerate, access, and maintain over time.
For some patients, that will be medication-based.
For others, it will require earlier integration of non-pharmacologic tools.
And for a subset of patients with clear contraindications, intolerance, or preference for non-drug approaches, neuromodulation may play a more central role than historically assumed.
The goal is not to redefine the algorithm, but to broaden it by including sTMS as an additional treatment option.
References
- American Headache Society. Consensus Statement: Integrating New Migraine Treatments Into Clinical Practice. Headache. 2021.
- American Academy of Neurology. Practice Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults.
- Puledda F, Goadsby PJ. Non-invasive neuromodulation for migraine and cluster headache: mechanisms and clinical applications. Cephalalgia. 2017;37(7):685–691.
- Moisset X, Pereira B, Ciampi de Andrade D, et al. Neuromodulation techniques for migraine: systematic review and meta-analysis. The Journal of Headache and Pain. 2020;21:142.
- Lipton RB, et al. Transcranial magnetic stimulation and migraine: clinical trial evidence base. The Lancet Neurology. 2010;9(4):373–380.
